ATE513564T1 - Immunogener rekombinanter antikörper - Google Patents

Immunogener rekombinanter antikörper

Info

Publication number
ATE513564T1
ATE513564T1 AT04727885T AT04727885T ATE513564T1 AT E513564 T1 ATE513564 T1 AT E513564T1 AT 04727885 T AT04727885 T AT 04727885T AT 04727885 T AT04727885 T AT 04727885T AT E513564 T1 ATE513564 T1 AT E513564T1
Authority
AT
Austria
Prior art keywords
recombinant antibody
immunogenic recombinant
immunogenic
antibody
recombinant
Prior art date
Application number
AT04727885T
Other languages
English (en)
Inventor
Hans Loibner
Gottfried Himmler
Guenter Waxenecker
Manfred Schuster
Thomas Putz
Original Assignee
Altropus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altropus Gmbh filed Critical Altropus Gmbh
Application granted granted Critical
Publication of ATE513564T1 publication Critical patent/ATE513564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04727885T 2003-04-17 2004-04-16 Immunogener rekombinanter antikörper ATE513564T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0059903A AT500650B1 (de) 2003-04-17 2003-04-17 Immunogener rekombinanter antikörper
PCT/EP2004/004059 WO2004091655A2 (en) 2003-04-17 2004-04-16 Immunogenic recombinant antibody

Publications (1)

Publication Number Publication Date
ATE513564T1 true ATE513564T1 (de) 2011-07-15

Family

ID=33163428

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0059903A AT500650B1 (de) 2003-04-17 2003-04-17 Immunogener rekombinanter antikörper
AT04727885T ATE513564T1 (de) 2003-04-17 2004-04-16 Immunogener rekombinanter antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0059903A AT500650B1 (de) 2003-04-17 2003-04-17 Immunogener rekombinanter antikörper

Country Status (4)

Country Link
US (1) US8034338B2 (de)
EP (2) EP2322214A1 (de)
AT (2) AT500650B1 (de)
WO (1) WO2004091655A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2006249087B2 (en) * 2005-05-20 2012-05-17 Lonza Biologics Plc High-level expression of recombinant antibody in a mammalian host cell
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
SG178845A1 (en) 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
WO2012154484A1 (en) * 2011-05-06 2012-11-15 Elwha Llc Compositions and methods for antibody and ligand identification
JP6578288B2 (ja) 2013-10-18 2019-09-18 ユニベルズィダード ドゥ ミンホＵｎｉｖｅｒｓｉｄａｄｅ Ｄｏ Ｍｉｎｈｏ ペプチド組成物およびその使用
WO2016003368A1 (en) * 2014-07-01 2016-01-07 Agency For Science, Technology And Research Optimized vectors for the production of recombinant proteins
US11365238B2 (en) 2015-12-07 2022-06-21 Camas Incorporated Sequencing chicken antibody repertoires following hyperimmunization and the identification of antigen-specific monoclonal antibodies
US11712410B2 (en) 2018-09-05 2023-08-01 K18, Inc. Composition for improving hair health
TW202216111A (zh) 2020-07-03 2022-05-01 米尼奧大學 香氛釋放機制、方法及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
WO1991017177A1 (en) 1990-05-04 1991-11-14 Baxter Diagnostics Inc. High affinity antibodies to small peptides
CZ286547B6 (cs) * 1992-05-22 2000-05-17 Novartis Ag Monoklonální protilátky a jejich použití
US20020146410A1 (en) * 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
WO1997015597A1 (en) 1995-10-25 1997-05-01 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
WO1997040140A1 (en) * 1996-04-22 1997-10-30 The Wistar Institute Of Anatomy And Biology Gd2 anti-idiotypic antibodies and uses thereof
WO1998011241A1 (en) 1996-09-16 1998-03-19 Merck Patent Gmbh Oligocistronic expression system for the production of heteromeric proteins
HK1044487B (zh) 1999-01-13 2005-09-16 伊格尼昂癌症治疗研发股份公司 抗体用於抗癌接种的用途
EP1218504B1 (de) 1999-09-21 2007-07-11 Genetics Institute, LLC Gl50 moleküle, sowie verwendungen derselben
AT409086B (de) 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
DE10059930A1 (de) * 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
US20040181475A1 (en) * 2003-03-14 2004-09-16 Ejaz Haroon Preferred stock securitization process

Also Published As

Publication number Publication date
EP1613349A2 (de) 2006-01-11
US20070258978A1 (en) 2007-11-08
EP1613349B1 (de) 2011-06-22
AT500650B1 (de) 2009-11-15
WO2004091655A2 (en) 2004-10-28
AT500650A1 (de) 2006-02-15
WO2004091655A3 (en) 2005-02-17
US8034338B2 (en) 2011-10-11
EP2322214A1 (de) 2011-05-18

Similar Documents

Publication Publication Date Title
EP1499352A4 (de) Rekombinante anti-interleukin-9-antikörper
DK1599504T3 (da) Modificeret antistof
NO20044347L (no) Anti-alfavbeta6-antistoff
DE602004022855D1 (de) Interleukin-10-antikörper
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
IS7547A (is) Ónæmisvaldandi samsetningar
ATE553775T1 (de) Impstoffzusammesetzung
NO20050132D0 (no) Vaksinesammensetning
EP1616881A4 (de) Anti-mpl-antikörper
IS7806A (is) Ónæmisvaldandi samsetning
NO20044326D0 (no) Virale antigener
DK1427444T3 (da) West-nil-vaccine
IS8387A (is) Ónæmisvaldandi samsetningar
NO20033882L (no) Vaksine
IS7831A (is) Bóluefni
EP1664117A4 (de) Immunogen
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1689869T3 (da) Rekombinant mikroorganisme
ATE513564T1 (de) Immunogener rekombinanter antikörper
DE60328408D1 (de) Impfstoff
NO20051561D0 (no) Vaksine
IS8325A (is) Bóluefni
DE60322070D1 (de) Rekombinante bcg-vakzine
DK1680502T3 (da) Rekombinant mikroorganisme
FR2871811B1 (fr) Endofucanase recombinante

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties